Pediatrix Medical Group, Inc.: Form 10-Q for the period ended Jun 30, 2018
Filed with the SEC on Aug 2, 2018 and accepted by EDGAR at Aug 2, 2018, 16:30 ET.
Management's discussion and analysis
As filed, 40,980 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K. As used in this Quarterly Report, the terms “MEDNAX”, the “Company”, “we”, “us” and “our” refer to the parent company, MEDNAX, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, “MDX”), together with MDX’s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (“affiliated professional contractors”). Certain subsidiaries of MDX have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The following discussion contains forward-looking statements. Please see the Company’s most recent Annual Report on Form 10-K, including Item 1A, Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see “Caution Concerning Forward-Looking Statements” below.
Overview
MEDNAX is a leading provider of physician services including newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 39 states and Puerto Rico. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units, to babies born prematurely or with medical complications; anesthesia care to patients in connection with surgical and other procedures, as well as pain management; radiology services including diagnostic imaging and interventional radiology; and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including those who provide pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat, pediatric ophthalmology and pediatric urology services. MEDNAX also provides teleradiology services in all 50 states, the District of Columbia and Puerto Rico through a network of affiliated radiologists. In addition to our national physician network, we provide services nationwide to healthcare facilities and physicians, including ours, through complementary businesses, consisting of a management services organization focusing on full-service revenue cycle management and a consulting services company.
2018 Acquisition Activity
During the six months ended June 30, 2018, we completed the acquisitions of five physician group practices, including two radiology practices, one neonatology practice and two pediatric subspecialty practices. Based on our experience, we expect that we can improve the results of all of our acquired physician practices through improved managed care contracting, improved collections, identification of growth initiatives, as well as, operating and cost savings based upon the significant infrastructure that we have developed. In addition, we believe that we bring a unique value proposition to radiology physician groups, in that we can provide not only practice support, but also teleradiology capabilities that can enhance a physician group’s efficiency, provide subspecialty access and help them grow and remain competitive. We believe that radiology physician group practice physicians can complement the staffing needs for our teleradiology services business during certain times, such as nights and weekends, when the group practice physicians are not providing services at their practices. Our results of operations for the three and six months ended June 30, 2018 include the results for these five acquisitions from their respective dates of acquisition and therefore are not comparable in some respects to our results of operations for prior periods.
Corporate and Operational Initiatives
We have developed a number of strategic initiatives across our organization, in both our corporate functions and our operational infrastructure, with a goal of generating improvements in our general and administrative expenses and improvements through operational plans. In our corporate departments, we are focused on best-in-class cost and service excellence in order to improve processes, use our resources more efficiently and utilize our scale more effectively in all areas of our operations. Within our operational infrastructure, we have developed specific operational plans within each of our service lines and affiliated physician practices, with specific milestones and regular reporting, with the goal of generating long-term operational improvements and fostering even greater collaboration across our national medical group. We are targeting annualized financial improvements related to these initiatives of $40 million within general and administrative expenses and $80 million in operational improvements by the end of 2019, although there is no assurance that these improvements will be obtained. We believe these strategic initiatives, together with our continued plans to invest in focused, targeted and strategic organic and acquisitive growth, position us well to deliver a differentiated value proposition to our stakeholders while continuing to provide the highest quality care for our patients.
Common Stock Repurchase Program
In July 2013, our board of directors authorized the repurchase of shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs. The share repurchase program allows us to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of our common stock to offset the dilutive impact from the issuance of shares, if any, related to our acquisition program. During the six months ended June 30, 2018, we repurchased 1.2 million shares of our common stock for $52.2 million, inclusive of 54,909 shares withheld to satisfy minimum statutory withholding obligations of $2.5 million in connection with the vesting of restricted stock and exercises of stock options during the three months ended June 30, 2018. The shares repurchased by us during the second quarter of 2018 completed the repurchases under the repurchase program with respect to issuances of shares under our equity compensation programs during 2018.
On August 2, 2018, we announced that our board of directors had authorized the repurchase of up to $500.0 million of shares of our common stock in addition to our existing share repurchase program. We intend to commence repurchases under this program in the near term.
We may utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.
General Economic Conditions and Other Factors
Our operations and performance depend significantly on economic conditions. During the three months ended June 30, 2018, the percentage of our patient service revenue being reimbursed under government-sponsored or funded healthcare programs (the “GHC Programs”), decreased as compared to the three months ended March 31, 2018 but increased as compared to the three months ended June 30, 2017. We could experience shifts toward GHC Programs and patient volumes could decline if economic conditions deteriorate or changes occur in population demographics within geographic locations in which we provide services. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, due to the rising costs of managed care premiums and patient responsibility amounts, we may experience lower net revenue resulting from increased bad debt due to patients’ inability to pay for certain services.
Healthcare Reform
The Patient Protection and Affordable Care Act (the “ACA”) contains a number of provisions that have affected us and, absent amendment or repeal, may continue to affect us over the next several years. These provisions include the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the Federal Civil False Claims Act (“FCA”) and other healthcare fraud and abuse laws. Moreover, we could be affected by potential changes to various aspects of the ACA, including subsidies, healthcare insurance marketplaces and Medicaid expansion.
The ACA remains subject to continuing legislative and administrative scrutiny, including efforts by the Republican-controlled Congress and the current Administration to amend or repeal a number of its provisions, as well as administrative actions delaying the effectiveness of key provisions. At the end of 2017, Congress repealed part of the ACA that required most individuals to purchase and maintain health insurance. If the ACA is repealed or further substantially modified, or if implementation of certain aspects of the ACA are diluted or delayed, such repeal, modification or delay may impact our business, financial condition, results of operations, cash flows and the trading price of our securities. We are unable to predict the impact of any repeal, modification or delay in the implementation of the ACA, including the repeal of the individual mandate, on us at this time.
In addition to the potential impacts to the ACA under the current Administration, there could be more sweeping changes to GHC Programs, such as a change in the structure of Medicaid by converting it into a block grant or instituting “per capita caps,” which could eliminate the guarantee that everyone who is eligible and applies for benefits would receive them and could potentially give states sweeping new authority to restrict eligibility, cut benefits and make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income.
As a result, we cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities.
The Medicare Access and CHIP Reauthorization Act
Medicare pays for most physician services based upon a national service-specific fee schedule. In 2015, Congress enacted the Medicare Access and CHIP Reauthorization Act (“MACRA,”) which provides physicians 0.5% annual increases in reimbursement through 2019 as Medicare transitions to a payment system designed to reward physicians for the quality of care provided, rather than the quantity of procedures performed. MACRA will require physicians to choose to participate in one of two payment formulas, Merit-Based Incentive Payment System (“MIPS”) or Alternative Payment Models (“APMs”). Beginning in 2019, MIPS will allow eligible physicians to receive incentive payments based on the achievement of certain quality and cost metrics, among other measures, and be reduced for those who are underperforming against those same metrics and measures. As an alternative, physicians can choose to participate in an Advanced APM. Advanced APMs are exempt from the MIPS requirements, and physicians who are meaningful participants in APMs will receive bonus payments from Medicare pursuant to the law. We currently anticipate that our affiliated physicians will be eligible to receive bonus payments in 2019 through participation in the MIPS, although the amounts of such bonus payments are not expected to be material. We will continue to operationalize the provisions of MACRA and assess any further changes to the law or additional regulations enacted pursuant to the law.
We cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that its provisions will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.
Medicaid Expansion
The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state’s historic eligibility levels to 133% of the federal poverty level. To date, 32 states and the District of Columbia have expanded Medicaid eligibility to cover this additional low income patient population, and other states are considering expansion. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level.
Medicare Sequestration
The Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, required across-the-board cuts (“sequestrations”) to Medicare reimbursement rates. These annual reductions of 2%, on average, apply to mandatory and discretionary spending through 2025. Unless Congress takes action in the future to modify these sequestrations, Medicare reimbursements will be reduced by 2%, on average, annually. However, this reduction in Medicare reimbursement rates is not expected to have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities.
Non-GAAP Measures
In our analysis of our results of operations, we use certain non-GAAP financial measures. Earnings before interest, taxes and depreciation and amortization (“EBITDA”) consists of net income before interest expense, income tax provision and depreciation and amortization. Prior to the fourth quarter of 2017, the Company had included immaterial investment and other income and equity in earnings of unconsolidated affiliates as a component of the interest expense adjustment within EBITDA. Beginning with the fourth quarter of 2017, the Company began excluding these items such that the interest expense adjustment represents only interest expense and has conformed its historical EBITDA calculations with the current presentation. Adjusted earnings per common share (“Adjusted EPS”) consists of diluted net income per common and common equivalent share adjusted for amortization expense and stock-based compensation expense.
We believe these measures, in addition to income from operations, net income and diluted net income per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis. These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these non-GAAP measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies.
For a reconciliation of each of EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three and six months ended June 30, 2018 and 2017, refer to the tables below (in thousands, except per share data). In addition, historical reconciliations of EBITDA and Adjusted EPS are available on our Internet website at www.mednax.com (http://www.mednax.com) under the Investors tab. Our Internet website and the information contained therein or connected thereto are not incorporated into or deemed a part of this Form 10-Q.
| Three Months Ended June 30, 2018 | 2017 | Six Months Ended June 30, 2018 | 2017 | |
|---|---|---|---|---|
| Net income | $79,412 | $63,698 | $142,840 | $118,389 |
| Interest expense | 21,604 | 18,535 | 41,539 | 36,287 |
| Income tax provision | 30,122 | 40,725 | 54,181 | 75,692 |
| Depreciation and amortization | 26,518 | 25,735 | 52,681 | 51,349 |
| EBITDA | $157,656 | $148,693 | $291,241 | $281,717 |
| Three Months Ended June 30, 2018 | 2017 | |
|---|---|---|
| Weighted average diluted shares outstanding | 93,529 | 92,812 |
| Net income and diluted net income per share | $79,412 $0.85 | $63,698 $0.69 |
| Adjustments: | ||
| Amortization (net of tax of $4,822 and $6,800) | 12,713 0.14 | 10,636 0.11 |
| Stock-based compensation (net of tax of $2,894 and $2,826) | 7,630 0.08 | 4,420 0.05 |
| Adjusted net income and diluted EPS | $99,755 $1.07 | $78,754 $0.85 |
| Six Months Ended June 30, 2018 | 2017 | |
|---|---|---|
| Weighted average diluted shares outstanding | 93,516 | 92,977 |
| Net income and diluted net income per share | $142,840 $1.53 | $118,389 $1.27 |
| Adjustments: | ||
| Amortization (net of tax of $9,586 and $13,644) | 25,273 0.27 | 21,340 0.23 |
| Stock-based compensation (net of tax of $5,609 and $5,764) | 14,790 0.16 | 9,017 0.10 |
| Adjusted net income and diluted EPS | $182,903 $1.96 | $148,746 $1.60 |
Results of Operations
Three Months Ended June 30, 2018 as Compared to Three Months Ended June 30, 2017
Our net revenue increased $73.0 million, or 8.7%, to $915.9 million for the three months ended June 30, 2018, as compared to $842.9 million for the same period in 2017. Of this $73.0 million increase, $46.7 million, or 5.5%, was attributable to revenue generated from acquisitions completed after March 31, 2017 and 26.3 million, or 3.2%, was attributable to an increase in same-unit net revenue. Same units are those units at which we provided services for the entire current period and the entire comparable period. The increase in same-unit net revenue was comprised of an increase of $15.5 million, or 1.9%, related to patient service volumes and a net increase of $10.8 million, or 1.3%, from net reimbursement-related factors. The increase in revenue of $15.5 million from patient service volumes was related to growth across all of our services. The net increase in revenue of $10.8 million related to net reimbursement-related factors was primarily due to modest improvements in managed care contracting and an increase in the administrative fees received from our hospital partners, partially offset by a decrease in revenue caused by an increase in the percentage of our patients enrolled in GHC Programs.
Practice salaries and benefits increased $59.6 million, or 10.6%, to $621.0 million for the three months ended June 30, 2018, as compared to $561.4 million for the same period in 2017. This $59.6 million increase was primarily attributable to increased costs associated with physicians and other staff to support organic-growth initiatives, acquisition-related growth and growth at our existing units, of which $50.2 million was related to salaries and $9.4 million was related to benefits and incentive compensation. We anticipate that we will continue to experience a higher rate of growth in clinician compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities. We anticipate that practice salaries and benefits expense for the third and fourth quarters of 2018 will continue to include salaries and benefit costs for certain physicians who will remain employed through December 31, 2018 despite the non-renewal of an anesthesia services contract by one of our hospital partners effective July 1, 2018, under which they had previously provided services.
Practice supplies and other operating expenses increased $0.9 million, or 3.1%, to $31.8 million for the three months ended June 30, 2018, as compared to $30.9 million for the same period in 2017. The increase was primarily attributable to practice supply, rent and other costs related to our acquisitions, partially offset by decreases at our existing units.
General and administrative expenses include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our physician practices and services, as well as those attributable to our non-physician service businesses. General and administrative expenses increased $4.9 million, or 4.8%, to $107.9 million for the three months ended June 30, 2018, as compared to $103.0 million for the same period in 2017. The increase of $4.9 million is attributable to the overall growth of the Company. Included within general and administrative expenses was an increase of $3.2 million of stock-based compensation expense primarily resulting from the change in timing of our annual equity grants from June to March in order to align the timing with other compensation related activities and a decrease of approximately $6.0 million in cost improvement as part of our corporate initiative. General and administrative expenses as a percentage of net revenue was 11.8% for the three months ended June 30, 2018, as compared to 12.2% for the same period in 2017.
Depreciation and amortization expense increased $0.8 million, or 3.0%, to $26.5 million for the three months ended June 30, 2018, as compared to $25.7 million for the same period in 2017. The increase was primarily attributable to the amortization of intangible assets related to acquisitions.
Income from operations increased $6.8 million, or 5.6%, to $128.7 million for the three months ended June 30, 2018, as compared to $121.9 million for the same period in 2017. Our operating margin was 14.1% for the three months ended June 30, 2018, as compared to 14.5% for the same period in 2017. The decrease of 41 basis points was primarily due to higher operating expense growth as compared to revenue growth.
Net non-operating expenses were $19.1 million for the three months ended June 30, 2018, as compared to $17.5 million for the same period in 2017. The net increase in non-operating expenses was primarily related to an increase in interest expense due to higher average interest rates on higher outstanding borrowings under our credit agreement (the “Credit Agreement”).
Our effective income tax rate was 27.5% and 39.0% for the three months ended June 30, 2018 and 2017, respectively. The decrease in our effective tax rate is primarily related to the reduction in the corporate tax rate enacted under the Tax Cuts and Jobs Act of 2017.
Net income was $79.4 million for the three months ended June 30, 2018, as compared to $63.7 million for the same period in 2017. EBITDA was $157.7 million for the three months ended June 30, 2018, as compared to $148.7 million for the same period in 2017.
Diluted net income per common and common equivalent share was $0.85 on weighted average shares outstanding of 93.5 million for the three months ended June 30, 2018, as compared to $0.69 on weighted average shares outstanding of 92.8 million for the same period in 2017. Adjusted EPS was $1.07 for the three months ended June 30, 2018, as compared to $0.85 for the same period in 2017.
Six Months Ended June 30, 2018 as Compared to Six Months Ended June 30, 2017
Our net revenue increased $139.2 million, or 8.3%, to $1.82 billion for the six months ended June 30, 2018, as compared to $1.68 billion for the same period in 2017. Of this $139.2 million increase, $84.6 million, or 4.9%, was attributable to revenue generated from acquisitions completed after December 31, 2016 and $54.6 million, or 3.4%, was attributable to an increase in same-unit net revenue. Same units are those units at which we provided services for the entire current period and the entire comparable period. The increase in same-unit net revenue was comprised of a net increase of $28.7 million, or 1.8%, related to patient service volumes and an increase of $25.9 million, or 1.6%, from net reimbursement-related factors. The increase in revenue of $28.7 million from patient service volumes was related to growth across almost all of our services. The net increase in revenue of $25.9 million related to net reimbursement-related factors was primarily due to modest improvements in managed care contracting and an increase in the administrative fees received from our hospital partners, partially offset by a decrease in revenue caused by an increase in the percentage of our patients enrolled in GHC Programs.
Practice salaries and benefits increased $119.0 million, or 10.5%, to $1.25 billion for the six months ended June 30, 2018, as compared to $1.13 billion for the same period in 2017. This $119.0 million increase was primarily attributable to increased costs associated with physicians and other staff primarily to support organic-growth initiatives, acquisition-related growth and growth at our existing units, of which $96.9 million was related to salaries and $22.1 million was related to benefits and incentive compensation. We anticipate that we will continue to experience a higher rate of growth in compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities. We anticipate that practice salaries and benefits expense for the third and fourth quarters of 2018 will continue to include salaries and benefit costs for certain physicians who will remain employed through December 31, 2018 despite the non-renewal of an anesthesia services contract with one of our hospital partners effective July 1, 2018, under which they had previously provided services.
Practice supplies and other operating expenses increased $3.8 million, or 6.5%, to $62.5 million for the six months ended June 30, 2018, as compared to $58.7 million for the same period in 2017. The increase was primarily attributable to practice supply, rent and other costs related to our acquisitions, partially offset by decrease at our existing units.
General and administrative expenses include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our physician practices and services, as well as those attributable to our non-physician service businesses. General and administrative expenses increased $9.9 million, or 4.8%, to $216.7 million for the six months ended June 30, 2018, as compared to $206.8 million for the same period in 2017. The net increase of $9.9 million is attributable to the overall growth of the Company, including growth from acquisitions. Included within general and administrative expenses was an increase of $5.4 million of stock-based compensation expense primarily resulting from the change in timing of our annual equity grants from June to March in order to align the timing with other compensation related activities and a decrease of $12.0 million in cost improvement as part of our corporate initiative. General and administrative expenses as a percentage of net revenue was 11.9% for the six months ended June 30, 2018, as compared to 12.3% for the same period in 2017.
Depreciation and amortization expense increased $1.4 million, or 2.6%, to $52.7 million for the six months ended June 30, 2018, as compared to $51.3 million for the same period in 2017. The increase was primarily attributable to the amortization of intangible assets related to acquisitions.
Income from operations increased $5.2 million, or 2.3%, to $233.1 million for the six months ended June 30, 2018, as compared to $227.9 million for the same period in 2017. Our operating margin was 12.8% for the six months ended June 30, 2018, as compared to 13.6% for the same period in 2017. The decrease of 76 basis points was due to higher operating expense growth as compared to revenue growth.
Net non-operating expenses were $36.1 million for the six months ended June 30, 2018, as compared to $33.9 million for the same period in 2018. The net increase in non-operating expenses was primarily related to an increase in interest expense due to higher average interest rates on higher outstanding borrowings under our Credit Agreement.
Our effective income tax rate was 27.5% and 39.0% for the six months ended June 30, 2018 and 2017, respectively. The decrease in our effective tax rate is primarily related to the reduction in the corporate tax rate enacted under the Tax Cuts and Jobs Act of 2017.
Net income was $142.8 million for the six months ended June 30, 2018, as compared to $118.4 million for the same period in 2017. EBITDA was $291.2 million for the six months ended June 30, 2018, as compared to $281.7 million for the same period in 2017.
Diluted net income per common and common equivalent share was $1.53 on weighted average shares outstanding of 93.5 million for the six months ended June 30, 2018, as compared to $1.27 on weighted average shares outstanding of 93.0 million for the same period in 2017. Adjusted EPS was $1.96 for the six months ended June 30, 2018, as compared to $1.60 for the same period in 2017.
Liquidity and Capital Resources
As of June 30, 2018, we had $38.1 million of cash and cash equivalents on hand as compared to $60.2 million at December 31, 2017. Additionally, we had working capital of $213.7 million at June 30, 2018, an increase of $117.9 million from working capital of $95.8 million at December 31, 2017. This net increase in working capital is primarily due to year-to-date earnings and net borrowings on our Credit Agreement, partially offset by the use of funds for repurchases of our common stock and acquisitions.
Cash Flows
Cash provided by (used in) operating, investing and financing activities is summarized as follows (in thousands):
| Six Months Ended June 30, 2018 | 2017 | |
|---|---|---|
| Operating activities | $21,604 | $115,813 |
| Investing activities | (38,974) | (139,821) |
| Financing activities | (4,774) | 8,733 |
17
Operating Activities
During the six months ended June 30, 2018, our net cash provided from operating activities was $21.6 million, compared to $115.8 million for the same period in 2017. The net decrease in cash provided of $94.2 million was primarily due to increases in accounts receivable, a decrease in cash flow from income taxes resulting from tax payments made in the first quarter of 2018 for 2017 taxes that were deferred by the Internal Revenue Service for companies impacted by the 2017 hurricanes, partially offset by an increase in cash flow related to higher earnings.
During the six months ended June 30, 2018, cash flow from accounts receivable decreased by $24.0 million, as compared to an increase of $18.4 million for the same period in 2017. The decrease in cash flow from accounts receivable for the six months ended June 30, 2018 was primarily due to increased ending accounts receivable balances at existing units resulting from higher same-unit revenue.
Days sales outstanding (“DSO”) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO was 52.5 days at June 30, 2018 as compared to 50.9 days at December 31, 2017. The increase in our DSO primarily related to the increases in our accounts receivable balances at existing units.
Investing Activities
During the six months ended June 30, 2018, our net cash used in investing activities of $39.0 million primarily included capital expenditures of $26.3 million, acquisition payments of $25.6 million and net purchases of $9.9 million related to the purchase and maturity of investments, partially offset by proceeds of $22.8 million related to the sale of the controlling interest in a group of assets to a third party.
Financing Activities
During the six months ended June 30, 2018, our net cash used in financing activities of $4.8 million consisted primarily of the repurchase of $52.2 million of our common stock, partially offset by net borrowings on our Credit Agreement of $39.0 million and proceeds of $9.4 million from the exercise of employee stock options and the issuance of common stock under our 1996 Non-Qualified Employee Stock Purchase Plan, as amended, and 2015 Non-Qualified Stock Purchase Plan.
Liquidity
Our Credit Agreement provides for a $2.0 billion unsecured revolving credit facility and includes a $37.5 million sub-facility for the issuance of letters of credit. The Credit Agreement matures on October 31, 2022 and is guaranteed by substantially all of our subsidiaries and affiliated professional contractors. At our option, borrowings under the Credit Agreement will bear interest at (i) the alternate base rate (defined as the higher of (a) the prime rate, (b) the Federal Funds Rate plus 1/2 of 1.00% and (c) LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated leverage ratio or (ii) the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.300% of the unused lending commitments, based on our consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, and restrictions on the ability to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement.
At June 30, 2018, we had an outstanding principal balance of $1.1 billion on our Credit Agreement. We also had outstanding letters of credit of $0.2 million which reduced the amount available on our Credit Agreement to $850.3 million at June 30, 2018.
At June 30, 2018, the outstanding principal balance on our 5.25% senior unsecured notes due 2023 (the “2023 Senior Notes”) was $750.0 million. Our obligations under the 2023 Senior Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Credit Agreement. Interest on the 2023 Senior Notes accrues at the rate of 5.25% per annum, or $39.4 million, and is payable semi-annually in arrears on June 1 and December 1.
The indenture under which the 2023 Senior Notes are issued, among other things, limits our ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions. Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2023 Senior Notes, upon the occurrence of a change in control of MEDNAX, we may be required to repurchase the 2023 Senior Notes at a purchase price equal to 101% of the aggregate principal amount of the 2023 Senior Notes repurchased plus accrued and unpaid interest.
At June 30, 2018, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under our Credit Agreement and the 2023 Senior Notes. We believe we will be in compliance with these covenants throughout 2018.
We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at June 30, 2018 was $242.9 million, of which $35.3 million is classified as a current liability within accounts payable and accrued expenses in the Condensed Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $16.7 million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies.
On August 2, 2018, we announced that our board of directors had authorized the repurchase of up to $500.0 million of shares of our common stock in addition to our existing share repurchase program. We intend to utilize various methods to effect the additional share repurchases, which are expected to commence in the near term. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.
We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Form 10-Q.
Caution Concerning Forward-Looking Statements
Certain information included or incorporated by reference in this Quarterly Report may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K, including the section entitled “Risk Factors.”
Market risk
As filed, 694 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt. We borrow under our Credit Agreement at various interest rate options based on the Alternate Base Rate or LIBOR rate depending on certain financial ratios. At June 30, 2018, the outstanding principal balance on our Credit Agreement was $1.1 billion. Considering the total outstanding balance of $1.1 billion, a 1.0% change in interest rates would result in an impact to income before income taxes of approximately $11 million per year.
Controls and procedures
As filed, 1,547 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this report.
Changes in Internal Controls Over Financial Reporting
No changes in our internal control over financial reporting occurred during the quarter ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 133 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2018-04-01 to 2018-06-30 | $128.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2018-01-01 to 2018-06-30 | $233.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-04-01 to 2018-06-30 | $21.6m | us-gaap:InterestExpense |
| Interest expense | 6 months2018-01-01 to 2018-06-30 | $41.5m | us-gaap:InterestExpense |
| Income tax | 3 months2018-04-01 to 2018-06-30 | $30.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2018-01-01 to 2018-06-30 | $54.2m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months2018-04-01 to 2018-06-30 | $0.85 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2018-01-01 to 2018-06-30 | $1.53 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-04-01 to 2018-06-30 | $0.85 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2018-01-01 to 2018-06-30 | $1.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-04-01 to 2018-06-30 | 93,529,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2018-01-01 to 2018-06-30 | 93,516,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2018-01-01 to 2018-06-30 | $21.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 6 months2018-01-01 to 2018-06-30 | $52.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2018-06-30 | $38.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-06-30 | $624.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-06-30 | $5.86bn | us-gaap:Assets |
| Current liabilities | At period end2018-06-30 | $411.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-06-30 | $2.67bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-06-30 | $3.19bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-18-236651. Last ingested by Listed: Oct 29, 2026, 07:14 ET. Listed shows no prices and gives no investment advice.